NCT04091022View on ClinicalTrials.gov

Topical Diclofenac and Topical DFMO Chemoprevention Trial in Subjects with a History of Skin Cancer

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

138

Participants

Timeline

Start Date

January 18, 2021

Primary Completion Date

November 1, 2025

Study Completion Date

December 1, 2025

Conditions
Non-melanoma Skin Cancer
Interventions
DRUG

Solaraze and Vaniqa

Solaraze-topical diclofenac 3% and Vaniqa-topical eflornithine hydrochloride Cream, 13.9% applied to bilateral arms for a period of 9 months

Trial Locations (2)

35233

Birmingham VA Medical Center, Birmingham

UAB Dermatology, Birmingham

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

collaborator

National Institutes of Health (NIH)

NIH

lead

University of Alabama at Birmingham

OTHER